- Home
- CGAU vs IMCR Comparison
CGAU vs IMCR Comparison
Compare CGAU & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGAU
- IMCR
- Stock Information
- Founded
- CGAU 2002
- IMCR 2008
- Country
- CGAU Canada
- IMCR United Kingdom
- Employees
- CGAU N/A
- IMCR N/A
- Industry
- CGAU Precious Metals
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CGAU Basic Materials
- IMCR Health Care
- Exchange
- CGAU Nasdaq
- IMCR Nasdaq
- Market Cap
- CGAU 1.3B
- IMCR 1.4B
- IPO Year
- CGAU N/A
- IMCR 2021
- Fundamental
- Price
- CGAU $6.34
- IMCR $29.67
- Analyst Decision
- CGAU Buy
- IMCR Buy
- Analyst Count
- CGAU 2
- IMCR 12
- Target Price
- CGAU $11.00
- IMCR $63.00
- AVG Volume (30 Days)
- CGAU 1.1M
- IMCR 372.2K
- Earning Date
- CGAU 05-13-2025
- IMCR 05-07-2025
- Dividend Yield
- CGAU 3.15%
- IMCR N/A
- EPS Growth
- CGAU N/A
- IMCR N/A
- EPS
- CGAU 0.35
- IMCR N/A
- Revenue
- CGAU $1,214,503,000.00
- IMCR $310,202,000.00
- Revenue This Year
- CGAU N/A
- IMCR $18.97
- Revenue Next Year
- CGAU $2.75
- IMCR $8.43
- P/E Ratio
- CGAU $18.03
- IMCR N/A
- Revenue Growth
- CGAU 10.92
- IMCR 24.36
- 52 Week Low
- CGAU $5.46
- IMCR $27.19
- 52 Week High
- CGAU $7.82
- IMCR $66.00
- Technical
- Relative Strength Index (RSI)
- CGAU 58.14
- IMCR 50.47
- Support Level
- CGAU $6.05
- IMCR $28.92
- Resistance Level
- CGAU $6.54
- IMCR $30.50
- Average True Range (ATR)
- CGAU 0.20
- IMCR 1.44
- MACD
- CGAU 0.06
- IMCR 0.09
- Stochastic Oscillator
- CGAU 79.80
- IMCR 46.17
About CGAU Centerra Gold Inc.
Centerra Gold Inc a gold mining and exploration company engaged in the operation, exploration, development, and acquisition of gold properties in Asia, North America, and other markets world-wide. The company reportable operating segments are Oksut; Mount; and Milligan Molybdenum. It derives maximum revenue from Oksut segment. Geographically, it operates in Turkey, United States, Canada and Other.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.